QCG
VERV

Quadrant Capital Group’s Verve Therapeutics VERV Stock Holding History

Quadrant Capital Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,518
Closed -$11.5K – 2581
2025
Q1 		$11.5K Hold
2,518
– – ﹤0.01% 2188
2024
Q4 		$14.2K Buy
2,518
+1,316
+109% +$7.42K ﹤0.01% 2016
2024
Q3 		$5.82K Sell
1,202
-216
-15% -$1.25K ﹤0.01% 2286
2024
Q2 		$6.92K Buy
1,418
+1,268
+845% +$7.97K ﹤0.01% 2219
2024
Q1 		$1.99K Hold
150
– – ﹤0.01% 2511
2023
Q4 		$2.09K Sell
150
-42
-22% -$521 ﹤0.01% 2466
2023
Q3 		$2.55K Hold
192
– – ﹤0.01% 2327
2023
Q2 		$3.6K Buy
+192
New +$3.2K ﹤0.01% 2281

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Quadrant Capital Group's VERV Position: Q2 2025 in Review

Quadrant Capital Group sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 2,518 shares — an estimated $11.5K sold.

Quadrant Capital Group first reported a position in VERV in Q2 2023 and held it in 8 quarters. The position peaked at $14.2K in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Quadrant Capital Group reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 2,518 Verve Therapeutics shares in Q2 2025, an estimated $11.5K.
  • Quadrant Capital Group first reported a position in Verve Therapeutics in Q2 2023 and held it in 8 quarters.
  • Quadrant Capital Group's Verve Therapeutics position peaked at $14.2K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.